For EU HealthCare professionals

BRILIQUE™, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

*For physicians in 27 member states of the EU, Norway, Iceland and Liechtenstein.

 


 

Welcome to the BRILIQUE™ website for European physicians.*

This healthcare website is a resource for European physicians* with an interest in BRILIQUE™ for the treatment of Acute Coronary Syndromes.

*Physicians in 27 member states of EU and Norway, Iceland and Liechtenstein.

Welcome to the BRILIQUE™ website for European healthcare professionals*

This website is a European information resource intended for European healthcare professionals* with an interest in BRILIQUE™ and the treatment of acute coronary syndromes. Please choose which site you require.

While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product labels of BRILIQUE™ may not be the same in different countries. Information on this site is based on the Summary of Product Characteristics (SPC) for BRILIQUE™ in the EU. Please refer to your local Prescribing Information for full details.

By clicking on the link below you are declaring and confirming that you are a healthcare professional.

Access to the BRILIQUE™ website for EU healthcare professionals.*

This website uses cookies to function and collect information on visitor activity. By continuing to use this website you acknowledge your consent to the placement and use of cookies. Further information on our cookie policy and how to delete them can be read within our Privacy Policy

Other BRILIQUE™ websites for healthcare professionals only:

Information for patients and members of the press:

Patients: The website is intended for healthcare professionals only. If you are a patient, you should visit the patient health international website.

If you are a patient, you should contact your physician if you have any questions related to symptomatic treatment of acute coronary syndromes, or any drug used to treat these conditions.

Press: If you are a member of the press, you should visit the AstraZeneca Press Office

*Physicians in the 27 member states of the EU and Norway, Iceland and Liechtenstein